An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective
Authors:
Open Access
- 26 November 2024
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 24 (1) , 1-13
Abstract
Background: Three recent randomized controlled trials demonstrated that, in patients with symptomatic paroxysmal atrial fibrillation (PAF), first-line pulmonary vein isolation with cryoballoon catheter ablation reduces atrial arrhythmia recurrence compared to initial antiarrhythmic drug (AAD) therapy. This study aimed to evaluate the cost-effectiveness of first-line cryoablation compared to first-line AADs from a German healthcare payer perspective. Methods: Individual patient-level data from 703 participants with untreated PAF enrolled into three randomized clinical trials (Cryo-FIRST, STOP AF First and EARLY-AF) were used to derive parameters for the cost-effectiveness model (CEM). The CEM structure consisted of a hybrid decision tree and Markov model. The decision tree (one-year time horizon) informed initial health state allocation in the first cycle of the Markov model (40-year time horizon; three-month cycle length). Health benefits were expressed in quality-adjusted life years (QALYs). Cost inputs were sourced from German diagnosis-related groups and the Institute for the Hospital Remuneration System (InEK). Costs and benefits were discounted at 3% per annum. Results: Cryoablation was cost-effective, incurring ~ €200 per patient while offering an increase in QALYs (~ 0.18) over a lifetime. This produced an average incremental cost-effectiveness ratio of ~ €1,000 per QALY gained. Individuals were expected to receive ~ 1.2 ablations over a lifetime, regardless of initial treatment. However, those initially treated with cryoablation as opposed to AADs experience 0.9 fewer re-ablations and a 45% reduction in time spent in AF health states. Conclusion: Initial rhythm control with cryoballoon ablation in symptomatic PAF is a cost-effective treatment option in a German healthcare setting.Keywords
This publication has 33 references indexed in Scilit:
- Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2)JAMA, 2014
- Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial FibrillationNew England Journal of Medicine, 2012
- Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value SetsValue in Health, 2012
- Population-Based Study of Acute- and Long-Term Care Costs after Stroke in Patients with AFInternational Journal of Stroke, 2012
- Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management StrategiesMayo Clinic Proceedings, 2009
- The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in GermanyValue in Health, 2009
- German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover ConsensusValue in Health, 2008
- The NICE Cost-Effectiveness ThresholdPharmacoEconomics, 2008
- Radiofrequency Ablation vs Antiarrhythmic Drugs as First-line Treatment of Symptomatic Atrial FibrillationJAMA, 2005
- Paroxysmal atrial fibrillationQJM: An International Journal of Medicine, 2001